Ysios Capital Investors

Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society. ... The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen ...

Headquarters: Spain
Investor Type: Technology - oriented Investor with Venture Investment Focus
Investment Stage: Early Stage Venture, Late Stage Venture, Venture
Employee Number: 11-50
Funding Status: N/A
Industry: Asset Management
Technology: N/A
Number Of Exists: 13
Founded Date: 2008-01-01